Metimazole Bağlı Vaskülit Gelişen Hashitoksikozisli Adölesan Hasta

Abstract

Birçok ülkede, çocuklarda hipertiroidizmde ilk seçenek tedavi metimazoldür. Metimazol ile tedavi sırasında bazı yan etkiler görülebilir. Sık görülen yan etkiler döküntü, kaşıntı, artralji, bulantı ve tat değişikliğidir. Diğer ciddi yan etkileri Steven Johnson Sendromu, trombositopeni, nötropeni ve vaskülittir. Burada; metimazole bağlı vaskülit gelişen16 yaşındaki kız hastayı tartışacağız. Hastamızda metimazole bağlı vaskülit tedaviden sonraki birinci ayda görülmüştür. Vaskülit semptomları tedavi kesiminden sonra hızlıca kaybolmuştur. Vaskülit metimazolün ağır bir yan etkisidir ve tedavi kesilmesini gerekmektedir.

Keywords

• Adölesan, Hipertiroidi, Metimazol, Vaskülit

Vasculitis Caused by Methimazole in an Adolescent Patient with Hashitoxicosis

Abstract

Methimazole therapy is the first-line treatment in children with hyperthyroidism in many countries. Treatment with methimazole may be accompanied by side effects. Common side effects include rash, pruritus, arthralgia, nausea, and reduced taste. Other serious side effects include the Stevens-Johnson Syndrome, thrombocytopenia, neutropenia, and vasculitis. Here, we report a 16-year-old girl with methimazole-induced vasculitis. The onset of vasculitis in our patient was one month after the initiation of methimazole therapy. The symptoms of vasculitis disappeared rapidly following cessation of treatment. Vasculitis is a serious side effect of methimazole and is an indication for prompt cessation of treatment

Keywords

• Adolescent, Hyperthyroidism, Methimazole, Vasculitis

References

1. A Fava, R Oliverio, S Giuliano, G Parlato, A Michniewicz, A Indrieri, et al. Clinical evolution of autoimmune thyroiditis in children and adolescents. Thyroid 2009;19:361-7.
2. Nabhan ZM, Kreher NC, Eugster EA. Hashitoxicosis in children: Clinical features and natural history. J Pediatri 2005;146:533–6.
3. Wasniewska M, Corrias A, Salerno M, Lombardo F, Aversa T, Mussa A. Outcomes of children with hashitoxicosis. Horm Res Paediatr 2012;77:36–40.
4. Burch HB, Burman KD, Cooper DS. A 2011 survey of clinical practice patterns in the management of Graves’ disease. J Clin Endocrinol Metab 2012;97:4549–58.
5. Cooper DS. Antithyroid drugs. N Engl J Med 2005;352:905–17.
6. Bahn Chair RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, et al; American Thyroid Association; American Association of Clinical Endocrinologists. Hyperthyroidism and other causes of thyrotoxicosis: Management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 2011;21:593–646.